| Line 10: |
Line 10: |
| | The HPV vaccine is being promoted as protection against cervical cancer, but Merck itself does not ensure protection in its package insert.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> Rather, this claim is based on research showing that 70% of cervical cancer cases also have prevalence of these four strains of HPV, but correlation is not necessarily causation.<ref>http://www.cancer.gov/cancertopics/factsheet/Risk/HPV</ref> Cervical cancer has been quickly declining in the United States ''without'' the vaccine. | | The HPV vaccine is being promoted as protection against cervical cancer, but Merck itself does not ensure protection in its package insert.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> Rather, this claim is based on research showing that 70% of cervical cancer cases also have prevalence of these four strains of HPV, but correlation is not necessarily causation.<ref>http://www.cancer.gov/cancertopics/factsheet/Risk/HPV</ref> Cervical cancer has been quickly declining in the United States ''without'' the vaccine. |
| | | | |
| − | The FDA approved this HPV vaccine without reviewing any epidemiological studies and after monitoring for only a brief period elevated [[antibody]] levels in recipients of the vaccine.<ref> http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm</ref> No tests were done, for example, to see if the vaccine causes cancer or birth defects in rats, though such tests would be easy for the FDA to require, if it weren't for the possibility that it might cause disapproval of the vaccine.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> | + | The FDA approved this HPV vaccine without reviewing any epidemiological studies, and after monitoring for only a brief period elevated [[antibody]] levels in recipients of the vaccine.<ref> http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm</ref> No tests were done, for example, to see if the vaccine causes cancer or birth defects in rats, though such tests would be easy for the FDA to require, if it weren't for the possibility that it might cause disapproval of the vaccine.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> |
| | | | |
| − | The long-term consequences of the HPV vaccine are not known. Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine, such as infertility or cancer. | + | The long-term consequences of the HPV vaccine are not known. Children in the 9-year-old age group have been monitored for only 18 months, and there have been no studies of possible longer-term risks of the vaccine, such as infertility or cancer. |
| | | | |
| | Merck sells Gardasil for $360 ($120 per shot in a three-shot series). Adding administrative costs, the overall cost to the public is $400-500 per child vaccinated. Doing the math, the cost of vaccinating 100 children will be at least $40,000, but only 3 out of that 100 will ever be exposed to the HPV types targeted by the vaccine. | | Merck sells Gardasil for $360 ($120 per shot in a three-shot series). Adding administrative costs, the overall cost to the public is $400-500 per child vaccinated. Doing the math, the cost of vaccinating 100 children will be at least $40,000, but only 3 out of that 100 will ever be exposed to the HPV types targeted by the vaccine. |